Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Development of the Osmium-191->Iridium-191m radionuclide generator. Annual report

Technical Report ·
OSTI ID:6834440
The use of the ultrashort-lived radionuclide IR-191m (T/sub 1/2/=5s) for radionuclide angiography results in a lower patient radiation dose, higher photon flux, and allows repeated studies that are not possible with the radionuclide currently employed for these studies (Tc-99m, T/sub 1/2/=6h). The Os-191->Ir-191m generator currently being used in clinical studies suffers, however, from low Ir-191m yield (10%), high Os-191 breakthrough (5 x 10/sup -3/%), and an eluent (at pH 1) that must be buffered prior to injection. Initial efforts to improve the performance of this generator met with only limited success. We have, therefore, concentrated on the development of a completely new generator system. In the last year these investigations have led to a new generator of improved Ir-191m yield (20 to 25%), dramatically lower Os-191 breakthrough (5 x 10/sup -4/%), and an eluent that does not require buffering prior to injection. In addition, this generator has been found to be stable for at least 10 days and does not require a scavenger column to achieve low breakthrough. Clinical studies have continued at Children's Hospital in pediatric patients and at Beth Israel Hospital in adult patients. 19 references, 1 figure, 10 tables.
Research Organization:
Harvard Medical School, Boston, MA (USA)
DOE Contract Number:
AC02-82ER60084
OSTI ID:
6834440
Report Number(s):
DOE/ER/60084-3; ON: DE84012460
Country of Publication:
United States
Language:
English